🇺🇸 FDA
Pipeline program

Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

NN1436-7727

Approved small_molecule active

Quick answer

Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution for Type 2 diabetes is a Approved program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Type 2 diabetes
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials